An empirical study of the prescription pattern of drugs for hematological malignancies in Japan from 2010-2014

Shoyo Shibata, Yusuke Wayama, Ai Tsuyuki, Maiko Matsushita, Koji Chiba, Eri Matsuki, Shinichiro Okamoto, Takeshi Suzuki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The number of elderly patients with hematologic malignancies has been steadily increasing with the aging of society. However, little research has been conducted to evaluate the prescription status of drugs for such diseases in Japan. Therefore, the aims of this study were to identify the patient population currently being prescribed drugs for hematologic malignancies in Japan and the direction of drug development. To examine the prescription pattern of drugs for the treatment of hematological malignancies in Japan from 2010-2014, we used the IMS Japan Pharmaceutical Market database and the Japanese Society of Hematology Clinical Practice Guidelines, and for drug development status, we used ClinicalTrials.gov and the University Hospital Medical Information Network Clinical Trials Registry. We found a significant upward trend in prescriptions for molecular-Targeted agents, which are typically prescribed over the long term, and a significant downward trend in chemotherapeutic agents, which are usually prescribed for the short term. We also found that recent drug development in hematological malignancies has focused on molecular-Targeted agents. These results suggest that drug development should be directed toward anti-Tumor agents in hematological malignancies that can help maintain and improve patients' QOL.

Original languageEnglish
Pages (from-to)894-901
Number of pages8
JournalBiological and Pharmaceutical Bulletin
Volume40
Issue number6
Publication statusPublished - 2017

Fingerprint

Prescription Drugs
Hematologic Neoplasms
Japan
Pharmaceutical Preparations
Pharmaceutical Databases
Information Services
Hematology
Practice Guidelines
Prescriptions
Registries
Clinical Trials
Research
Population
Neoplasms

Keywords

  • Drug development
  • Japan
  • Prescription pattern
  • Unmet medical need

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

An empirical study of the prescription pattern of drugs for hematological malignancies in Japan from 2010-2014. / Shibata, Shoyo; Wayama, Yusuke; Tsuyuki, Ai; Matsushita, Maiko; Chiba, Koji; Matsuki, Eri; Okamoto, Shinichiro; Suzuki, Takeshi.

In: Biological and Pharmaceutical Bulletin, Vol. 40, No. 6, 2017, p. 894-901.

Research output: Contribution to journalArticle

@article{49336b9e10d145e88c5e57a13b845ab3,
title = "An empirical study of the prescription pattern of drugs for hematological malignancies in Japan from 2010-2014",
abstract = "The number of elderly patients with hematologic malignancies has been steadily increasing with the aging of society. However, little research has been conducted to evaluate the prescription status of drugs for such diseases in Japan. Therefore, the aims of this study were to identify the patient population currently being prescribed drugs for hematologic malignancies in Japan and the direction of drug development. To examine the prescription pattern of drugs for the treatment of hematological malignancies in Japan from 2010-2014, we used the IMS Japan Pharmaceutical Market database and the Japanese Society of Hematology Clinical Practice Guidelines, and for drug development status, we used ClinicalTrials.gov and the University Hospital Medical Information Network Clinical Trials Registry. We found a significant upward trend in prescriptions for molecular-Targeted agents, which are typically prescribed over the long term, and a significant downward trend in chemotherapeutic agents, which are usually prescribed for the short term. We also found that recent drug development in hematological malignancies has focused on molecular-Targeted agents. These results suggest that drug development should be directed toward anti-Tumor agents in hematological malignancies that can help maintain and improve patients' QOL.",
keywords = "Drug development, Japan, Prescription pattern, Unmet medical need",
author = "Shoyo Shibata and Yusuke Wayama and Ai Tsuyuki and Maiko Matsushita and Koji Chiba and Eri Matsuki and Shinichiro Okamoto and Takeshi Suzuki",
year = "2017",
language = "English",
volume = "40",
pages = "894--901",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "6",

}

TY - JOUR

T1 - An empirical study of the prescription pattern of drugs for hematological malignancies in Japan from 2010-2014

AU - Shibata, Shoyo

AU - Wayama, Yusuke

AU - Tsuyuki, Ai

AU - Matsushita, Maiko

AU - Chiba, Koji

AU - Matsuki, Eri

AU - Okamoto, Shinichiro

AU - Suzuki, Takeshi

PY - 2017

Y1 - 2017

N2 - The number of elderly patients with hematologic malignancies has been steadily increasing with the aging of society. However, little research has been conducted to evaluate the prescription status of drugs for such diseases in Japan. Therefore, the aims of this study were to identify the patient population currently being prescribed drugs for hematologic malignancies in Japan and the direction of drug development. To examine the prescription pattern of drugs for the treatment of hematological malignancies in Japan from 2010-2014, we used the IMS Japan Pharmaceutical Market database and the Japanese Society of Hematology Clinical Practice Guidelines, and for drug development status, we used ClinicalTrials.gov and the University Hospital Medical Information Network Clinical Trials Registry. We found a significant upward trend in prescriptions for molecular-Targeted agents, which are typically prescribed over the long term, and a significant downward trend in chemotherapeutic agents, which are usually prescribed for the short term. We also found that recent drug development in hematological malignancies has focused on molecular-Targeted agents. These results suggest that drug development should be directed toward anti-Tumor agents in hematological malignancies that can help maintain and improve patients' QOL.

AB - The number of elderly patients with hematologic malignancies has been steadily increasing with the aging of society. However, little research has been conducted to evaluate the prescription status of drugs for such diseases in Japan. Therefore, the aims of this study were to identify the patient population currently being prescribed drugs for hematologic malignancies in Japan and the direction of drug development. To examine the prescription pattern of drugs for the treatment of hematological malignancies in Japan from 2010-2014, we used the IMS Japan Pharmaceutical Market database and the Japanese Society of Hematology Clinical Practice Guidelines, and for drug development status, we used ClinicalTrials.gov and the University Hospital Medical Information Network Clinical Trials Registry. We found a significant upward trend in prescriptions for molecular-Targeted agents, which are typically prescribed over the long term, and a significant downward trend in chemotherapeutic agents, which are usually prescribed for the short term. We also found that recent drug development in hematological malignancies has focused on molecular-Targeted agents. These results suggest that drug development should be directed toward anti-Tumor agents in hematological malignancies that can help maintain and improve patients' QOL.

KW - Drug development

KW - Japan

KW - Prescription pattern

KW - Unmet medical need

UR - http://www.scopus.com/inward/record.url?scp=85019994248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019994248&partnerID=8YFLogxK

M3 - Article

C2 - 28566631

AN - SCOPUS:85019994248

VL - 40

SP - 894

EP - 901

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 6

ER -